NasdaqGM:HRMYPharmaceuticals
Harmony Biosciences Holdings (HRMY) Valuation After Earnings, 2026 WAKIX Guidance And Upcoming Investor Conferences
Harmony Biosciences Holdings (HRMY) is back in focus after reporting fourth quarter and full year 2025 results, alongside reaffirmed 2026 WAKIX revenue guidance and plans to speak at several high profile healthcare investor conferences.
See our latest analysis for Harmony Biosciences Holdings.
The latest earnings, the reiterated WAKIX revenue outlook for 2026, and the company’s upcoming presence at major healthcare conferences all come against a backdrop of weaker recent share price momentum...